- Home
- INSM vs ZBRA Comparison
INSM vs ZBRA Comparison
Compare INSM & ZBRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- ZBRA
- Stock Information
- Founded
- INSM 1988
- ZBRA 1969
- Country
- INSM United States
- ZBRA United States
- Employees
- INSM N/A
- ZBRA N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- ZBRA Industrial Machinery/Components
- Sector
- INSM Health Care
- ZBRA Industrials
- Exchange
- INSM Nasdaq
- ZBRA Nasdaq
- Market Cap
- INSM 19.1B
- ZBRA 16.8B
- IPO Year
- INSM 2000
- ZBRA 1991
- Fundamental
- Price
- INSM $103.95
- ZBRA $335.69
- Analyst Decision
- INSM Strong Buy
- ZBRA Buy
- Analyst Count
- INSM 17
- ZBRA 9
- Target Price
- INSM $109.20
- ZBRA $341.78
- AVG Volume (30 Days)
- INSM 4.1M
- ZBRA 422.6K
- Earning Date
- INSM 08-07-2025
- ZBRA 08-05-2025
- Dividend Yield
- INSM N/A
- ZBRA N/A
- EPS Growth
- INSM N/A
- ZBRA 109.28
- EPS
- INSM N/A
- ZBRA 10.57
- Revenue
- INSM $381,030,000.00
- ZBRA $5,114,000,000.00
- Revenue This Year
- INSM $28.17
- ZBRA $7.67
- Revenue Next Year
- INSM $120.09
- ZBRA $6.08
- P/E Ratio
- INSM N/A
- ZBRA $31.76
- Revenue Growth
- INSM 20.77
- ZBRA 17.45
- 52 Week Low
- INSM $60.40
- ZBRA $205.73
- 52 Week High
- INSM $106.83
- ZBRA $427.76
- Technical
- Relative Strength Index (RSI)
- INSM 66.75
- ZBRA 66.10
- Support Level
- INSM $101.55
- ZBRA $324.46
- Resistance Level
- INSM $103.74
- ZBRA $337.07
- Average True Range (ATR)
- INSM 2.58
- ZBRA 7.35
- MACD
- INSM -0.49
- ZBRA 0.06
- Stochastic Oscillator
- INSM 86.11
- ZBRA 94.34
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About ZBRA Zebra Technologies Corporation
Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.